ProCE Banner Activity

Combined Analysis of ATLAS, FLAIR, ATLAS-2M: Efficacy and Safety of Switch to LA CAB + RPV by BMI Class

Slideset Download
Across phase III/IIIb trials through Week 48, LA CAB + RPV maintained high rates of virologic suppression across dosing strategies and BMI categories; no participant with BMI ≥30 kg/m2 as only baseline risk factor met CVF criterion.

Released: November 05, 2021

Expiration: November 04, 2022

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp

ViiV Healthcare